ANCA-associated vasculitis (AAV) patients with neurological manifestations are more than three times more likely to have large blood vessel…
Andrea Lobo, PhD
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo, PhD
While it’s rare in children, ANCA-associated vasculitis (AAV)-related glomerulonephritis, that is, an inflammation of the glomeruli, the kidneys’ filtering…
People with ANCA-associated vasculitis (AAV) who are positive for antibodies against both myeloperoxidase (MPO) and proteinase 3 (PR3) show…
The risk of poor outcomes after a kidney transplant is considerably higher for ANCA-associated vasculitis (AAV) patients with kidney…
Tavneos (avacopan) safely and effectively promotes clinical remission in people with newly diagnosed or relapsing ANCA-associated vasculitis (AAV),…
Occupational exposure to silica, one of the most common minerals in the earth’s crust, may lead to microscopic polyangiitis…
ANCA-associated vasculitis (AAV) relapses occur more frequently during the summer and spring, particularly for people with granulomatosis with polyangiitis…
A 64-year-old man with severe granulomatosis with polyangiitis (GPA) saw his condition improve with the use of a triple…
The severity of anemia, or low levels of oxygen-carrying hemoglobin, is significantly associated with certain kidney lesions in people with…
Treatment with rituximab has a similar efficacy to cyclophosphamide — both of them standard immunosuppressive therapies — in reducing short-time…